Jiangsu Genscend Biopharmaceutical Co., Ltd

This study tests a new medicine called GS101 against the standard treatment Dupixent for people with moderate-to-severe atopic dermatitis (eczema). About 572 adults aged 18 to 75 will receive either GS101 or Dupixent injections for up to a year. The main goal is to see if GS101 c…